For Medtech manufacturers navigating EU MDR, IVDR, UKCA, and global regulatory frameworks. Eclevar Medtech provides the strategic architecture to secure your approvals.
Under the EU MDR 2017/745, Technical Files face unprecedented scrutiny. Manufacturers frequently suffer lengthy delays not because their device is unsafe, but because their documentation is fragmented, forcing the Notified Body reviewer to search for conformity links.
Yumiko Kida brings the exact mindset of an NB reviewer to your regulatory strategy. She conducts ruthless, reviewer-grade gap analyses before submission, ensuring your Technical File directly maps to GSPRs and avoids the critical discrepancies that trigger Major Non-Conformities (NCRs).
Conducted rigorous assessments (Annex II & III) for over 30 medical device clients, directly deciding on MDD and EU MDR conformity.
Executed deep Technical File reviews under MDD. Managed hundreds of complaints and controlled documents (ISO 13485 / 14971).
Mastered complex international compliance introducing European and US medical materials to the highly regulated Japanese market (PMDA).
In the EU MDR era, compliance is no longer a static goal. It is a continuous cycle of clinical evidence generation and risk management. Eclevar Medtech does not just fill forms; we architect Technical Documentation that withstands the most rigorous audits.
Success rate in CE Mark transitions for our core clients since 2022.
Direct internal expertise from former Notified Body senior reviewers.
Average reduction in 'Time-to-Submission' through automated gap-closure.
Unified strategy covering EU, UKCA, and Japan PMDA markets.
Most Major Non-Conformities (NCRs) are not caused by a lack of data, but by a lack of narrative alignment. A CER that does not talk to your Risk Management file, or a Technical File that misses the "State of the Art" context, is a red flag. We build a cohesive regulatory story where every document reinforces your safety claims.
We perform a "mock-audit" of your technical documentation against Annex II & III. We do not just point out gaps; we provide the exact technical and clinical wording required to close them.
Defending a file is as important as writing it. We act as your strategic shield, managing EC/Notified Body queries, leading clarification meetings, and negotiating clinical evidence requirements.
Rule 11 for software? Rule 8 for implants? We help you navigate the complex MDR classification logic and decide whether you need a full Clinical Investigation or a PMCF-driven pathway.
Beyond Europe. We design "Global Regulatory Roadmaps" that align EU MDR, UKCA, and PMDA requirements into a single, unified clinical data architecture to save you time and millions in R&D.
Experts from TÜV SÜD and AKRA TEAM highlight that regulatory delays often stem from strategic missteps early in the process.
"We are probably Class IIa" is an expensive assumption. Proper classification is the foundation of a secure regulatory pathway.
Notified Bodies reject files where clinical evaluation claims do not perfectly match risk documentation. This causes massive delays.
Data collected outside Europe (FDA/PMDA) can be utilized for EU MDR compliance, provided it is relevant and properly bridged.
| Focus Area | Old Directive (MDD) | New Regulation (MDR) |
|---|---|---|
| Clinical Evidence | Equivalence was the default. Often based on lite data. | Clinical Data is mandatory. Equivalence is strictly limited (Annex XIV). |
| Technical Documentation | Siloed documents. Less focus on lifecycle. | Unified Technical File. Dynamic lifecycle integration (PMS/PMCF). |
| Notified Body Scrutiny | Sampling audits. Predictable review times. | Unannounced audits. Deep technical and clinical review of every file. |
| Post-Market (PMS) | Passive reporting of complaints. | Active PMS & PMCF. Continuous data collection to justify the CE Mark. |
We analyze existing documentation, clinical data, and risk files to identify the shortest path to CE Mark.
We structure the Clinical Evaluation Plan (CEP) and map GSPR requirements for a bulletproof File.
Our experts draft the CER and Technical Documentation using language optimized for NB acceptance.
We lead the defense during the audit phase, managing all queries until the final certificate is issued.
Rule 11 has moved almost all SaMD to Class IIa or higher. We help you define your 'Intended Purpose' carefully to ensure the correct classification while preparing the rigorous clinical data now required.
Yes. Legacy devices (MDD) have no grandfathering under MDR. We conduct a Gap Analysis of your current data and build a clinical bridging strategy to minimize new trial requirements.
Absolutely. We act as your technical experts during audits. We lead the response strategy to NB questions, significantly reducing the risk of a Major NCR.
Get a strategic roadmap tailored to your device class and target markets. Let us discuss your regulatory journey.
Consult a Regulatory Strategist
